<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi> is a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> syndrome predisposing to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We studied 82 North American and Australian <z:chebi fb="0" ids="18022">SCN</z:chebi> patients enrolled in the Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> International Registry who were on long-term treatment with granulocyte colony-stimulating factor and for whom the neutrophil elastase (ELA2) gene was sequenced </plain></SENT>
<SENT sid="2" pm="."><plain>There was no significant difference in the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in patients with mutant versus <z:mp ids='MP_0002169'>wild-type</z:mp> ELA2: the respective cumulative incidences at 15 years were 36% and 25% (P = 0.96) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with either mutant or <z:mp ids='MP_0002169'>wild-type</z:mp> ELA2 should be followed closely for leukaemic transformation </plain></SENT>
</text></document>